Literature DB >> 23772618

HIV and co-infections.

Christina C Chang1, Megan Crane, Jingling Zhou, Michael Mina, Jeffrey J Post, Barbara A Cameron, Andrew R Lloyd, Anthony Jaworowski, Martyn A French, Sharon R Lewin.   

Abstract

Despite significant reductions in morbidity and mortality secondary to availability of effective combination anti-retroviral therapy (cART), human immunodeficiency virus (HIV) infection still accounts for 1.5 million deaths annually. The majority of deaths occur in sub-Saharan Africa where rates of opportunistic co-infections are disproportionately high. In this review, we discuss the immunopathogenesis of five common infections that cause significant morbidity in HIV-infected patients globally. These include co-infection with Mycobacterium tuberculosis, Cryptococcus neoformans, hepatitis B virus, hepatitis C virus, and Plasmodium falciparum. Specifically, we review the natural history of each co-infection in the setting of HIV, the specific immune defects induced by HIV, the effects of cART on the immune response to the co-infection, the pathogenesis of immune restoration disease (IRD) associated with each infection, and advances in the areas of prevention of each co-infection via vaccination. Finally, we discuss the opportunities and gaps in knowledge for future research.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23772618      PMCID: PMC3697435          DOI: 10.1111/imr.12063

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  339 in total

1.  Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues.

Authors:  Luz Martín-Carbonero; Tiago Teixeira; Eva Poveda; Zulema Plaza; Eugenia Vispo; Juan González-Lahoz; Vincent Soriano
Journal:  AIDS       Date:  2011-01-02       Impact factor: 4.177

2.  TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

Authors:  Risini D Weeratna; Shawn R Makinen; Michael J McCluskie; Heather L Davis
Journal:  Vaccine       Date:  2005-07-18       Impact factor: 3.641

3.  Urinary lipoarabinomannan as predictor for the tuberculosis immune reconstitution inflammatory syndrome.

Authors:  Anali Conesa-Botella; Marguerite Massinga Loembé; Yukari C Manabe; William Worodria; Doreen Mazakpwe; Kenneth Luzinda; Harriet Mayanja-Kizza; Mitra Miri; Olive Mbabazi; Olivier Koole; Luc Kestens; Robert Colebunders
Journal:  J Acquir Immune Defic Syndr       Date:  2011-12-15       Impact factor: 3.731

4.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

5.  Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.

Authors:  L Kosi; T Reiberger; B A Payer; K Grabmeier-Pfistershammer; R Strassl; A Rieger; M Peck-Radosavljevic
Journal:  J Viral Hepat       Date:  2012-03-15       Impact factor: 3.728

6.  Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy.

Authors:  Julian H Elliott; Khol Vohith; Sarun Saramony; Chin Savuth; Chan Dara; Chel Sarim; Sarah Huffam; Robert Oelrichs; Pouv Sophea; Vonthanak Saphonn; John Kaldor; David A Cooper; Mean Chhi Vun; Martyn A French
Journal:  J Infect Dis       Date:  2009-12-01       Impact factor: 5.226

7.  Expression of the CXCR3 ligand I-TAC by hepatocytes in chronic hepatitis C and its correlation with hepatic inflammation.

Authors:  Karla J Helbig; Andrew Ruszkiewicz; Ljiljana Semendric; Hugh A J Harley; Shaun R McColl; Michael R Beard
Journal:  Hepatology       Date:  2004-05       Impact factor: 17.425

8.  Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models.

Authors:  Camaron R Hole; Floyd L Wormley
Journal:  Front Microbiol       Date:  2012-08-28       Impact factor: 5.640

9.  Analysis of successful immune responses in persons infected with hepatitis C virus.

Authors:  F Lechner; D K Wong; P R Dunbar; R Chapman; R T Chung; P Dohrenwend; G Robbins; R Phillips; P Klenerman; B D Walker
Journal:  J Exp Med       Date:  2000-05-01       Impact factor: 14.307

10.  Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage.

Authors:  Claire Dunn; Maurizia Brunetto; Gary Reynolds; Theodoros Christophides; Patrick T Kennedy; Pietro Lampertico; Abhishek Das; A Ross Lopes; Persephone Borrow; Kevin Williams; Elizabeth Humphreys; Simon Afford; David H Adams; Antonio Bertoletti; Mala K Maini
Journal:  J Exp Med       Date:  2007-03-12       Impact factor: 14.307

View more
  42 in total

1.  A Viral Exposure Signature Defines Early Onset of Hepatocellular Carcinoma.

Authors:  Jinping Liu; Wei Tang; Anuradha Budhu; Marshonna Forgues; Maria O Hernandez; Julián Candia; Yujin Kim; Elise D Bowman; Stefan Ambs; Yongmei Zhao; Bao Tran; Xiaolin Wu; Christopher Koh; Pallavi Surana; T Jake Liang; Maria Guarnera; Dean Mann; Manoj Rajaure; Tim F Greten; Zhanwei Wang; Herbert Yu; Xin Wei Wang
Journal:  Cell       Date:  2020-06-10       Impact factor: 41.582

Review 2.  Periodontal and other oral manifestations of immunodeficiency diseases.

Authors:  M E Peacock; R M Arce; C W Cutler
Journal:  Oral Dis       Date:  2016-10-10       Impact factor: 3.511

3.  Chronic Lymphocytic Choriomeningitis Infection Causes Susceptibility to Mousepox and Impairs Natural Killer Cell Maturation and Function.

Authors:  Pedro Alves-Peixoto; Maria Férez; Cory J Knudson; Colby Stotesbury; Carolina R Melo-Silva; Eric B Wong; Margarida Correia-Neves; Luis J Sigal
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

4.  Fungal immunology in clinical practice: Magical realism or practical reality?

Authors:  Christina C Chang; Stuart M Levitz
Journal:  Med Mycol       Date:  2019-06-01       Impact factor: 4.076

5.  A novel molecule with notable activity against multi-drug resistant tuberculosis.

Authors:  Vasu Nair; Maurice O Okello; Naveen K Mangu; Byung I Seo; Machhindra G Gund
Journal:  Bioorg Med Chem Lett       Date:  2015-01-28       Impact factor: 2.823

Review 6.  A Call to Arms: Quest for a Cryptococcal Vaccine.

Authors:  Marley C Caballero Van Dyke; Floyd L Wormley
Journal:  Trends Microbiol       Date:  2017-11-02       Impact factor: 17.079

7.  Temporal trends in areas at risk for concomitant tuberculosis in a hyperendemic municipality in the Amazon region of Brazil.

Authors:  Alexandre Tadashi Inomata Bruce; Thais Zamboni Berra; Felipe Lima Dos Santos; Yan Mathias Alves; Ludmilla Leidianne Limirio Souza; Antônio Carlos Vieira Ramos; Luiz Henrique Arroyo; Juliane de Almeida Crispim; Ione Carvalho Pinto; Pedro Fredemir Palha; Aline Aparecida Monroe; Mellina Yamamura; Regina Célia Fiorati; Ana Carolina Scarpel Moncaio; Dulce Maria de Oliveira Gomes; Ricardo Alexandre Arcêncio
Journal:  Infect Dis Poverty       Date:  2020-08-10       Impact factor: 4.520

8.  Loss of Resistance to Mousepox during Chronic Lymphocytic Choriomeningitis Virus Infection Is Associated with Impaired T-Cell Responses and Can Be Rescued by Immunization.

Authors:  Pedro Alves-Peixoto; Maria Férez; Cory J Knudson; Carolina R Melo-Silva; Colby Stotesbury; Eric B Wong; Margarida Correia-Neves; Luis J Sigal
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

9.  Mechanisms of residual immune activation in HIV-1-infected human lymphoid tissue ex vivo.

Authors:  Vincenzo Mercurio; Wendy Fitzgerald; Christophe Vanpouille; Ivan Molodtsov; Leonid Margolis
Journal:  AIDS       Date:  2021-07-01       Impact factor: 4.632

10.  Persistent Immune Activation in HIV-1-Infected Ex Vivo Model Tissues Subjected to Antiretroviral Therapy: Soluble and Extracellular Vesicle-Associated Cytokines.

Authors:  Vincenzo Mercurio; Wendy Fitzgerald; Ivan Molodtsov; Leonid Margolis
Journal:  J Acquir Immune Defic Syndr       Date:  2020-05-01       Impact factor: 3.771

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.